Genentech joins immune tolerance field with Parvus hookup

Genentech
Roche's James Sabry called Parvus' approach “potentially transformative." (Genentech)

Genentech has teamed up with Parvus Therapeutics to develop immune tolerance drugs. The Roche subsidiary put together an $800 million-plus deal to work with Parvus on drugs to treat autoimmune diseases.

Parvus is one of a clutch of biotechs including Anokion, AnTolRx and Topas Therapeutics that have used immune tolerance skills to catch the attention of big biopharma companies. In Parvus' case, its know-how has manifested in the creation of Navacims, drugs designed to turn effector T cells into regulatory T cells and thereby block the attacks on self-antigens that underpin autoimmune diseases. 

Novartis bought into the idea in 2017, securing the rights to Parvus’ lead Type 1 diabetes drug. And Roche has now followed its Swiss neighbor, signing off on a deal that could give its Genentech unit a source of drugs against inflammatory bowel disease, autoimmune liver diseases and celiac disease.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Genentech is making an upfront payment to secure the deal, but the meat of the $800 million-plus total value touted by Parvus is likely tied to research, development and commercialization milestone payments. Parvus is in line to receive milestones for each disease area covered by the deal.

To pocket those payments, Parvus will need to use its platform to identify Navacims against the three diseases and take them up to the end of phase 1. That done, Genentech will step in to take the drugs through phase 2 and beyond, awarding milestone payments to Parvus as it goes. 

James Sabry, global head of pharma partnering at Roche, talked up Parvus’ technology, calling it a “potentially transformative approach for treating autoimmune diseases by inducing immune tolerance without causing generalized immune suppression.”

Parvus is yet to generate clinical data to back up such talk. The programs covered by the Novartis and Genentech deals, which span from lead candidate selection to preclinical development, comprise all of the biotech’s publicly disclosed pipeline. But Sabry and his colleagues have seen enough promise in the early-stage data to spark their interest. 

“In preclinical testing, Parvus’ platform has shown the ability to induce and expand disease-specific regulatory T cells, which restore immune system balance and halt the autoimmune disease process,” Sabry said in a statement.

Other immune tolerance biotechs have similar aspirations and are going after an overlapping set of indications. These efforts remain in the early stages of R&D, but a who’s who of big biopharma firms have already signed up to support the programs. 

Suggested Articles

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.